Adagene (ADAG) Competitors $1.98 +0.04 (+2.06%) Closing price 10/3/2025 03:55 PM EasternExtended Trading$1.99 +0.01 (+0.56%) As of 10/3/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. LXEO, BNTC, DMAC, ALT, CGEM, RCKT, LBRX, TVRD, IMRX, and CTNMShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Lexeo Therapeutics (LXEO), Benitec Biopharma (BNTC), DiaMedica Therapeutics (DMAC), Altimmune (ALT), Cullinan Therapeutics (CGEM), Rocket Pharmaceuticals (RCKT), LB Pharmaceuticals (LBRX), Tvardi Therapeutics (TVRD), Immuneering (IMRX), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors Lexeo Therapeutics Benitec Biopharma DiaMedica Therapeutics Altimmune Cullinan Therapeutics Rocket Pharmaceuticals LB Pharmaceuticals Tvardi Therapeutics Immuneering Contineum Therapeutics Adagene (NASDAQ:ADAG) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation. Is ADAG or LXEO more profitable? Adagene's return on equity of 0.00% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Lexeo Therapeutics N/A -94.65%-73.36% Which has stronger valuation & earnings, ADAG or LXEO? Adagene has higher earnings, but lower revenue than Lexeo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$100K933.17-$33.42MN/AN/ALexeo Therapeutics$650K549.97-$98.33M-$3.26-2.03 Which has more risk and volatility, ADAG or LXEO? Adagene has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Does the media refer more to ADAG or LXEO? In the previous week, Adagene had 4 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for Adagene and 0 mentions for Lexeo Therapeutics. Adagene's average media sentiment score of 0.69 beat Lexeo Therapeutics' score of 0.00 indicating that Adagene is being referred to more favorably in the media. Company Overall Sentiment Adagene Positive Lexeo Therapeutics Neutral Do institutionals and insiders hold more shares of ADAG or LXEO? 9.5% of Adagene shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend ADAG or LXEO? Adagene currently has a consensus target price of $7.00, suggesting a potential upside of 253.54%. Lexeo Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 131.62%. Given Adagene's higher probable upside, research analysts clearly believe Adagene is more favorable than Lexeo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Lexeo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 SummaryAdagene beats Lexeo Therapeutics on 9 of the 14 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdageneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.32M$3.36B$6.12B$10.58BDividend YieldN/A2.28%5.65%4.69%P/E RatioN/A22.2886.9626.71Price / Sales933.17461.37605.88130.98Price / CashN/A47.8637.9061.31Price / Book1.749.9312.556.55Net Income-$33.42M-$52.80M$3.31B$277.50M7 Day Performance1.02%5.22%4.28%2.42%1 Month Performance-10.00%10.61%6.90%8.63%1 Year Performance-10.41%25.03%70.54%31.60% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.7787 of 5 stars$1.98+2.1%$7.00+253.5%-11.6%$93.32M$100K0.00260Short Interest ↑LXEOLexeo Therapeutics2.1608 of 5 stars$6.66-1.6%$15.33+130.2%-23.6%$365.59M$650K-2.0458Positive NewsBNTCBenitec Biopharma1.9958 of 5 stars$13.99+2.1%$24.80+77.3%+46.1%$359.63M$80K-9.5220DMACDiaMedica Therapeutics2.5447 of 5 stars$6.91-0.4%$12.33+78.5%+62.2%$358.72MN/A-10.0120News CoveragePositive NewsAnalyst UpgradeALTAltimmune3.2486 of 5 stars$3.79-5.3%$17.40+359.1%-37.2%$353.03M$20K-3.2150CGEMCullinan Therapeutics2.162 of 5 stars$5.97+0.2%$26.00+335.5%-63.9%$352.08MN/A-1.8530RCKTRocket Pharmaceuticals4.7739 of 5 stars$3.28+0.6%$16.73+410.2%-80.8%$351.77MN/A-1.31240News CoveragePositive NewsAnalyst ForecastLBRXLB PharmaceuticalsN/A$15.24-1.3%N/AN/A$346.52MN/A0.0016TVRDTvardi Therapeutics3.3102 of 5 stars$36.90+1.6%$64.25+74.1%N/A$340.59M$7.14M0.0080News CoverageGap UpIMRXImmuneering3.913 of 5 stars$6.75-16.5%$16.40+143.0%+144.9%$335.89MN/A-3.5760Analyst ForecastShort Interest ↑High Trading VolumeCTNMContineum Therapeutics2.9833 of 5 stars$11.82-0.8%$22.20+87.8%-33.2%$334.26M$50M-5.3731Positive News Related Companies and Tools Related Companies LXEO Competitors BNTC Competitors DMAC Competitors ALT Competitors CGEM Competitors RCKT Competitors LBRX Competitors TVRD Competitors IMRX Competitors CTNM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAG Stock Alerts